Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Prostatic Neoplasms 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Somatostatinoma 1Recurrence 1Pituitary Neoplasms 1Optic Nerve Glioma 1Lymphoma, Mantle-Cell 1Growth Hormone-Secreting Pituitary Adenoma 1Colonic Neoplasms 1Carcinoma, Neuroendocrine 1Carcinoma, Merkel Cell 1Carcinoma, Islet Cell 1

Interventions

Rituximab 5Peripheral Blood Stem Cell Transplantation 4Cyclophosphamide 4ibrutinib 2fludarabine phosphate 2Tacrolimus 2Pentetic Acid 2Methotrexate 2Melphalan 2Lenalidomide 2Etoposide 2Doxorubicin 2Dexamethasone 2Cytarabine 2Carmustine 2umbralisib 1ublituximab 1sargramostim 1romidepsin 1ethanolamine oleate 1antineoplaston AS 2-1 1antineoplaston A10 1Whole-Body Irradiation 1Vincristine 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Transplantation 1Thiotepa 1Thalidomide 1Sulfamethoxazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Waldenstrom Macroglobulinemia × antineoplaston A10 × Clear all
NCT00003512 2018-02-05

Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia

Burzynski Research Institute

Phase 2 Withdrawn
Lymphoid

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡